Astellas Pharma Inc.
ALPMF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $2,627 | $3,038 | $3,450 | $3,488 |
| - Cash | $188 | $336 | $377 | $316 |
| + Debt | $831 | $1,006 | $200 | $213 |
| Enterprise Value | $3,270 | $3,708 | $3,273 | $3,385 |
| Revenue | $1,912 | $1,604 | $1,519 | $1,296 |
| % Growth | 19.2% | 5.6% | 17.2% | – |
| Gross Profit | $1,563 | $1,311 | $1,230 | $1,043 |
| % Margin | 81.7% | 81.8% | 81% | 80.5% |
| EBITDA | $248 | $195 | $337 | $298 |
| % Margin | 13% | 12.1% | 22.2% | 23% |
| Net Income | $51 | $17 | $99 | $124 |
| % Margin | 2.7% | 1.1% | 6.5% | 9.6% |
| EPS Diluted | 28.24 | 9.47 | 54.09 | 67.05 |
| % Growth | 198.2% | -82.5% | -19.3% | – |
| Operating Cash Flow | $195 | $172 | $328 | $257 |
| Capital Expenditures | -$57 | -$82 | -$89 | -$76 |
| Free Cash Flow | $137 | $90 | $239 | $181 |